文献速递糖尿病

钠-葡萄糖协同转运蛋白2抑制剂作为成人1型糖尿病辅助治疗的真实世界疗效与安全性:欧洲两中心经验

Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience.
PubMed 文献 · Diabetes Care · 2022-01-01

这项欧洲两中心回顾性队列研究纳入199例起始SGLT2i(钠-葡萄糖协同转运蛋白2抑制剂)辅助胰岛素治疗的成人1型糖尿病患者,12个月后平均HbA1c降低0.5%、体重降低2.9 kg、每日胰岛素用量减少8.5%;57例(28.6%)报告不良事件,包括45例生殖器感染(22.6%)、5例酮症(2.5%)和7例糖尿病酮症酸中毒(DKA)(3.5%),未报告严重低血糖事件。

要点

  • 12个月后平均HbA1c降低0.5%、体重降低2.9 kg、每日胰岛素用量减少8.5%。
  • 基线HbA1c>8%者HbA1c降幅最大(-0.7%),BMI>27 kg/m2者体重降幅最大(-3.5 kg)。
  • 57例(28.6%)报告不良事件,其中生殖器感染45例(22.6%)、酮症5例(2.5%)、DKA 7例(3.5%)。

核心结论

  • 真实世界数据显示SGLT2i在1型糖尿病中降低HbA1c、体重和胰岛素需求的结果令人鼓舞。
  • 基线HbA1c和BMI较高的个体获益更明显。
  • 尽管采取了教育措施,DKA仍是主要担忧。
  • 仍需进一步的真实世界证据评估SGLT2i的长期效应及其对肾脏-心血管结局的影响。

研究设计与样本

  • 欧洲两中心回顾性队列研究。
  • 纳入199例起始SGLT2i作为胰岛素辅助治疗的成人1型糖尿病患者。
  • 收集人口学、HbA1c、体重、胰岛素使用、肾功能和不良事件数据。
  • 进行亚组分析以识别获益最大和不良事件风险更高的人群。

主要发现

  • 12个月后平均HbA1c降低0.5%、体重降低2.9 kg、每日胰岛素用量减少8.5%。
  • 基线HbA1c>8%的个体HbA1c降幅最大(-0.7% [64 mmol/mol])。
  • BMI>27 kg/m2的受试者体重降幅最大(-3.5 kg)。
  • 基线eGFR<90 mL/min/1.73 m2的个体eGFR升高4.5 mL/min/1.73 m2,而UACR>15 mg/g的个体UACR降低16.6 mg/g。
  • 57例(28.6%)报告不良事件:45例生殖器感染(22.6%)、5例酮症(2.5%)、7例DKA(3.5%);未报告严重低血糖事件。

关键数值与推荐

  • 总体12个月平均HbA1c降低0.5%。
  • 基线HbA1c>8%者HbA1c降低0.7%(64 mmol/mol)。
  • 总体12个月平均体重降低2.9 kg;BMI>27 kg/m2者体重降低3.5 kg。
  • 总体12个月每日胰岛素用量减少8.5%。
  • 基线eGFR<90 mL/min/1.73 m2者eGFR升高4.5 mL/min/1.73 m2;UACR>15 mg/g者UACR降低16.6 mg/g。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 仍需进一步的真实世界证据评估SGLT2i的长期效应及其对肾脏-心血管结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate real-world efficacy and safety of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in combination with insulin in people with type 1 diabetes. RESEARCH DESIGN AND METHODS: We conducted a retrospective cohort European two-center study. Data on demographics, HbA1c, weight, insulin use, renal function, and adverse events were collected for 199 adults with type 1 diabetes who initiated a SGLT2i adjunct to insulin. Subgroup analyses were performed to identify who benefited most and who was more at risk for adverse events. RESULTS: Overall, significant reductions in mean HbA1c (-0.5%), weight (-2.9 kg), and daily insulin (-8.5%) were achieved after 12 months. The greatest reduction in HbA1c was obtained in individuals with baseline HbA1c >8% (-0.7% [64 mmol/mol]). The most weight loss was observed in subjects with BMI >27 kg/m2 (-3.5 kg). Individuals with baseline estimated glomerular filtration rate (eGFR) <90 mL/min/1.73 m2 showed an increase in eGFR (4.5 mL/min/1.73 m2), whereas those with urinary albumin-to-creatinine ratio (UACR) >15 mg/g showed a decrease in UACR (-16.6 mg/g). Fifty-seven individuals (28.6%) reported adverse events: 45 with genital infections (22.6%), 5 ketosis episodes (2.5%), and 7 diabetic ketoacidosis (DKA) (3.5%). No severe hypoglycemia events were reported. CONCLUSIONS: Our real-world data on SGLT2i showed promising results in reductions in HbA1c, weight, and insulin requirements in type 1 diabetes. Benefits were more pronounced in individuals with higher baseline HbA1c and BMI. DKA remained a major concern, despite educational measures. Further real-life evidence is still required for evaluation of SGLT2i longer-term effects and their impact on reno-cardiovascular outcomes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Palanca A, van Nes F, Pardo F, et al. Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience. Diabetes Care. 2022. PMID: 35061022. doi:10.2337/dc21-1584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。